Banner
References
Terapia farmacologica
published in September - October 2004 - in Il Fisioterapista - issue n.5

There are no translations available.

Bibliografia

  • Alberts JMC, Paimela L, Kurki P et al. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60: 453-8.

  • American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46(2): 328-46.

  • Carteron NL. Cytokines in rheumatoid arthritis: trials and tribulations. Mol Med Today 2000; 6: 315-23.

  • Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am J Ther 2001; 8: 123-43.

  • Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 2: the newer drugs and drugs strategies. Am J Ther 2001; 8: 163-79.

  • Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin receptor antagonist (IL-1Ra), in combination with methotrexate. Results of a twenty-four-week, multicenter, randomized, double blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-24.

  • Dayer J-M, Bresnihan B. Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum 2002; 46: 574-8.

  • Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 2002; 61 Suppl 2: ii2-7.

  • Kalden JR. How do the biologics fit into the current DMARD armamentarium? J Rheumatol 2001; 28 (Supp 62 ): 27-35.

  • Keating GM, Perry CM. Infliximab. An updated review of its use in Crohn’s disease and rheumatoid arthritis. BioDrugs 2002; 16: 111-48.

  • Mladenovic V, Domljan Z, Rozman B et al. Safety and effectiveness of leflunomide in the treatment of patients with rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38: 1595-603.

  • Moreland LW, Cohen SB, Baumgartner SW et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238-44.

  • Pincus T, O’Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Int Med 1999; 131: 768-74.

  • Scott DL, Smolen JS, Kalden JR et al. Treatment of active rheumatoid arthritis with leflunomide : two year follow up of a double blind, placebo controlled versus sulfasalazine. Ann Rheum Dis 2001; 60: 913-23.

  • Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 43: 495-505.

  • Skapedo A, Kalden JR et al. Treatment of rheumatoid arthritis in the third millennium. Scand J Rheumatol 2001; 30: 249-54.

  • Studio ANTARES (agg. 13/11/02): http://www.reumatologia.it

  • Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human antitumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant Methotrexate. The ARMADA trial. Arthritis Rheum 2003; 48: 35-45.

  • Witter J. Drug development in rheumatoid arthritis. Curr Opin Rheumatol 2002; 14: 276-80.


 
There are no translations available.